Expanded antibody portfolio for drug and biologics monitoring

Bio-Rad Laboratories has broadened its portfolio of recombinant monoclonal antibodies used in bioanalysis and drug monitoring, adding new anti-idiotypic and anti-Fc mutation products to support the detection of biologic therapeutics.

The expanded range includes antibodies targeting a series of clinically relevant biologics, alongside a new recombinant antibody for the GLP-1 receptor agonist dulaglutide. The company has also introduced its first anti-Fc mutation antibody panel, designed to detect YTE-modified antibodies through recognition of specific Fc region substitutions that can extend drug half-life.

These highly specific, non-animal derived antibodies are intended for use in preclinical and clinical pharmacokinetic (PK) and anti-drug antibody (ADA) assays, supporting therapeutic drug monitoring across biologics and biosimilars. The YTE-focused panel enables more precise measurement of modified therapeutics in serum, supporting the development of PK bridging ELISAs for free drug quantification. 

“With over 350 antibodies across more than 50 specificities, our portfolio continues to evolve to meet the needs of modern biologics development,” said Hilary Mavor, Marketing Director, Life Science Group at Bio-Rad Laboratories. “This expansion reflects our move beyond traditional anti-idiotypic antibodies into more advanced drug formats, including GLP-1 and Fc-modified therapeutics.”

The updated portfolio strengthens Bio-Rad’s offering for researchers developing and validating bioanalytical assays in an increasingly complex biologics landscape.

More information online